文献速递消化系统肿瘤

CpG甲基化特征预测早期肝细胞癌复发:多中心研究结果

CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study.
PubMed 文献 · J Clin Oncol · 2017-01-09

该多中心研究纳入四个独立中心的576例早期肝细胞癌患者,分三阶段筛选并验证CpG甲基化特征。基于三个CpG位点构建的MSEH特征可将患者分为高、低复发风险组,并在内部及两个外部队列中验证。包含MSEH、肿瘤分化、肝硬化、乙肝表面抗原和抗病毒治疗的列线图可预测5年无复发生存。

要点

  • 基于三个CpG位点的MSEH特征可区分早期肝细胞癌高、低复发风险组。
  • MSEH在内部验证队列和两个外部验证队列中均显示预测复发性能。
  • 包含MSEH及临床因素的列线图可预测5年无复发生存。

核心结论

  • MSEH这一基于三个CpG位点的特征有助于预测早期肝细胞癌患者的复发。

研究设计与样本

  • 多中心研究纳入四个独立中心的576例早期肝细胞癌患者,分发现、训练和验证三个阶段。
  • 发现阶段用Illumina Methylation 450k Beadchip分析66例肿瘤样本,采用LASSO和SVM-RFE两种算法筛选显著CpG。
  • 训练阶段用惩罚Cox回归将CpG进一步缩小至140例样本。
  • 验证阶段用内部队列(n=141)和两个外部队列(n=191和n=104)验证候选CpG。

主要发现

  • LASSO和SVM-RFE算法共选出46个CpG,训练阶段突出三个CpG对应SCAN结构域包含3、Src同源3结构域生长因子受体结合2样相互作用蛋白1和肽酶抑制剂3。
  • 基于三个CpG构建的MSEH在训练队列中将患者分为高、低复发风险组(P < .001)。
  • MSEH性能在内部队列(P < .001)和两个外部队列(P < .001;P = .002)中得到验证。
  • 包含MSEH、肿瘤分化、肝硬化、乙肝表面抗原和抗病毒治疗的列线图在训练队列中预测5年无复发生存,在三个验证队列中表现良好(一致性指数分别为0.725、0.697和0.693)。

关键数值与推荐

  • MSEH将患者分为高复发风险组和低复发风险组,训练队列P < .001。
  • MSEH验证:内部队列P < .001,外部队列P < .001和P = .002。
  • 列线图一致性指数在三个验证队列分别为0.725、0.697和0.693。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Early-stage hepatocellular carcinoma (E-HCC) is being diagnosed increasingly, and in one half of diagnosed patients, recurrence will develop. Thus, it is urgent to identify recurrence-related markers. We investigated the effectiveness of CpG methylation in predicting recurrence for patients with E-HCCs. Patients and Methods In total, 576 patients with E-HCC from four independent centers were sorted by three phases. In the discovery phase, 66 tumor samples were analyzed using the Illumina Methylation 450k Beadchip. Two algorithms, Least Absolute Shrinkage and Selector Operation and Support Vector Machine-Recursive Feature Elimination, were used to select significant CpGs. In the training phase, penalized Cox regression was used to further narrow CpGs into 140 samples. In the validation phase, candidate CpGs were validated using an internal cohort (n = 141) and two external cohorts (n = 191 and n =104). Results After combining the 46 CpGs selected by the Least Absolute Shrinkage and Selector Operation and the Support Vector Machine-Recursive Feature Elimination algorithms, three CpGs corresponding to SCAN domain containing 3, Src homology 3-domain growth factor receptor-bound 2-like interacting protein 1, and peptidase inhibitor 3 were highlighted as candidate predictors in the training phase. On the basis of the three CpGs, a methylation signature for E-HCC (MSEH) was developed to classify patients into high- and low-risk recurrence groups in the training cohort ( P < .001). The performance of MSEH was validated in the internal cohort ( P < .001) and in the two external cohorts ( P < .001; P = .002). Furthermore, a nomogram comprising MSEH, tumor differentiation, cirrhosis, hepatitis B virus surface antigen, and antivirus therapy was generated to predict the 5-year recurrence-free survival in the training cohort, and it performed well in the three validation cohorts (concordance index: 0.725, 0.697, and 0.693, respectively). Conclusion MSEH, a three-CpG-based signature, is useful in predicting recurrence for patients with E-HCC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Qiu J, Peng B, Tang Y, et al. CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study. J Clin Oncol. 2017. PMID: 28068175. doi:10.1200/JCO.2016.68.2153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。